At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Talimogene Laherparepvec +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas
In Brief
A Phase 2 clinical trial evaluating Talimogene Laherparepvec and Radiotherapy for Soft Tissue Sarcoma. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The purpose of this research study is to determine the safety and tolerability of talimogene laherparepvec when combined with radiation therapy. Approximately 30 people will take part in this study conducted by investigators at the University of Iowa.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSoft Tissue Sarcoma
CountriesUnited States
CollaboratorsAmgen
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartJul 2015
Primary CompletionJan 2019
Study CompletionMar 2023
TodayJul 2026
First PostedMay 25, 2015
Enrollment StartJul 13, 2015
Primary CompletionJan 22, 2019
Study CompletionMar 10, 2023
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 11.1 years ago
Interventions
Talimogene Laherparepvecdrug
Talimogene Laherparepvec
Radiotherapyradiation
Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.